A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

NCT02756247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: Buparlisib
DRUG: Ibrutinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]